{"filing":{"accession_number":"0001193125-26-405580","cik":"0001607678","ticker":"VKTX","company_name":"Viking Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-23","primary_document":"vktx-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/vktx-20260923.htm"},"events":[{"id":35516,"run_id":32715,"accession_number":"0001193125-26-405580","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Viking Therapeutics entered into underwriting agreements for a $225 million convertible senior notes offering due 2032 (approximately $251 million net proceeds) and a concurrent equity offering of 7.9 million shares at $35 per share (approximately $297 million net proceeds), representing a combined material capital raise of approximately $548 million in gross proceeds.","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39590,"accession_number":"0001193125-26-405580","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into underwriting agreements for both an equity offering (7.9 million shares at $35/share, ~$297M net proceeds) and a debt offering ($225M convertible senior notes due 2032, ~$251M net proceeds). While both offerings are material capital-raising events, the Item 1.01 classification and the detailed indenture terms for the convertible notes make the debt issuance the primary event. The combined offerings total approximately $548M in gross proceeds, representing a material capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:31:17.136576+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39591,"accession_number":"0001193125-26-405580","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 explicitly addresses \"Creation of a Direct Financial Obligation,\" and the section references a \"Debt Offering\" disclosed in Item 1.01, indicating Viking Therapeutics has issued new debt securities. The forward-looking statements reference \"anticipated use of proceeds from the Debt Offering,\" confirming a material debt issuance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:31:17.136576+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39590,"accession_number":"0001193125-26-405580","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into underwriting agreements for both an equity offering (7.9 million shares at $35/share, ~$297M net proceeds) and a debt offering ($225M convertible senior notes due 2032, ~$251M net proceeds). While both offerings are material capital-raising events, the Item 1.01 classification and the detailed indenture terms for the convertible notes make the debt issuance the primary event. The combined offerings total approximately $548M in gross proceeds, representing a material capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:31:17.136576+00:00","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-09-28"},{"id":39591,"accession_number":"0001193125-26-405580","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 explicitly addresses \"Creation of a Direct Financial Obligation,\" and the section references a \"Debt Offering\" disclosed in Item 1.01, indicating Viking Therapeutics has issued new debt securities. The forward-looking statements reference \"anticipated use of proceeds from the Debt Offering,\" confirming a material debt issuance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:31:17.136576+00:00","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-09-28"}]}